Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

because there’s only one semaglutide, and that’s produced by Novo Nordisk, and we don’t sell that to others.” Compounded drugs are made by pharmacies or manufacturers other than the companies that ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...